复发性卵巢癌患者的常规临床实践：TROCADERO研究结果

Routine Clinical Practice for Patients With Recurrent Ovarian Carcinoma: Results From the TROCADERO Study.

作者信息

Freyer Gilles, Ray-Coquard Isabelle, Fischer Dorothea, Martín Antonio González, Kielhorn Adrian, Chia Victoria, Nanayakkara Nuwan, Taylor Aliki

机构信息

*Institut de Cancérologie des HCL and †Centre Léon Bérard, Université de Lyon, Lyon, France; ‡Universitätsklinikum Schleswig-Holstein, Klinik für Frauenheilkunde und Geburtshilfe, Campus Lübeck, Lübeck, Germany; §MD Anderson Cancer Center, Madrid, Spain; ∥Amgen Inc., Thousand Oaks; and ¶Quintiles, San Diego, CA; and #Amgen Inc., Uxbridge, United Kingdom.

出版信息

Int J Gynecol Cancer. 2016 Feb;26(2):240-7. doi: 10.1097/IGC.0000000000000590.

DOI:10.1097/IGC.0000000000000590

PMID:26745696

Abstract

OBJECTIVE

Treatment options for patients with recurrent ovarian carcinoma are diverse, and different therapies are recommended based on platinum-free interval (PFI). Data examining the association between platinum sensitivity, treatment strategy, and outcomes are limited, particularly for partially platinum-sensitive (PPS) patients. This study characterized clinical features and outcomes in patients with recurrent ovarian carcinoma in the context of sensitivity to platinum-based therapy.

METHODS

Anonymized case records were obtained from eligible European medical sites. Eligible patients were 18 years or older with epithelial ovarian carcinoma who had received 1 or more platinum-based therapies and had 1 or more subsequent relapses. Patient records were categorized by PFI and analyzed based on demographic and clinical data using descriptive statistics.

RESULTS

There was no difference between PFI in PPS patients receiving platinum versus nonplatinum therapy (8.9 [range, 6.0-12.0] and 8.3 [range, 6.0-11.3] months, respectively). Overall survival in patients with platinum-sensitive, PPS, platinum-resistant, and platinum-refractory disease was 43.0 (95% confidence interval [95% CI], 25.1-42.3), 20.5 (95% CI, 17.7-24.8), 12.7 (95% CI, 10.4-14.2), and 9.8 (95% CI, 6.6-14.9) months, respectively. Among PPS patients, overall survival was 23.5 (95% CI, 18.4-37.3) and 18.7 (95% CI, 11.0-23.5) months for those who received platinum and nonplatinum-based therapy, respectively. No demographic or clinical characteristics were identified that indicated a difference between PPS patients who received platinum-based therapy versus those who did not.

CONCLUSIONS

Partially platinum-sensitive patients with recurrent ovarian carcinoma who received platinum-based therapy had improved outcomes compared with those who did not. No clear demographic criteria for choosing platinum- versus nonplatinum-based therapy for PPS patients were identified from patient records.

摘要

目的

复发性卵巢癌患者的治疗选择多种多样，基于无铂间期（PFI）推荐不同的治疗方法。关于铂敏感性、治疗策略和预后之间关联的数据有限，尤其是对于部分铂敏感（PPS）患者。本研究描述了复发性卵巢癌患者在对铂类疗法敏感情况下的临床特征和预后。

方法

从符合条件的欧洲医疗站点获取匿名病例记录。符合条件的患者年龄在18岁及以上，患有上皮性卵巢癌，接受过1种或更多铂类疗法且有1次或更多次后续复发。患者记录按PFI分类，并根据人口统计学和临床数据使用描述性统计进行分析。

结果

接受铂类与非铂类治疗的PPS患者的PFI无差异（分别为8.9[范围6.0 - 12.0]个月和8.3[范围6.0 - 11.3]个月）。铂敏感、PPS、铂耐药和铂难治性疾病患者的总生存期分别为43.0（95%置信区间[95%CI]，25.1 - 42.3）、20.5（95%CI，17.7 - 24.8）、12.7（95%CI，10.4 - 14.2）和9.8（95%CI，6.6 - 14.9）个月。在PPS患者中，接受铂类和非铂类治疗的患者总生存期分别为23.5（95%CI，18.4 - 37.3）和18.7（95%CI，11.0 - 23.5）个月。未发现人口统计学或临床特征表明接受铂类疗法的PPS患者与未接受铂类疗法的患者之间存在差异。